Westbourne Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.67M | Sell |
6,625
-300
| -4% | -$64.5K | 0.46% | 39 |
|
|
2026
Q1 | $1.51M | Hold |
6,925
| – | – | 0.44% | 40 |
|
|
2025
Q4 | $1.58M | Hold |
6,925
| – | – | 0.44% | 40 |
|
|
2025
Q3 | $1.6M | Sell |
6,925
-50
| -0.7% | -$10.2K | 0.45% | 38 |
|
|
2025
Q2 | $1.29M | Sell |
6,975
-300
| -4% | -$55.8K | 0.39% | 44 |
|
|
2025
Q1 | $1.52M | Sell |
7,275
-10
| -0.1% | -$1.94K | 0.54% | 39 |
|
|
2024
Q4 | $1.29M | Sell |
7,285
-65
| -0.9% | -$12K | 0.44% | 42 |
|
|
2024
Q3 | $1.45M | Sell |
7,350
-150
| -2% | -$28K | 0.51% | 40 |
|
|
2024
Q2 | $1.29M | Sell |
7,500
-100
| -1% | -$16.6K | 0.47% | 43 |
|
|
2024
Q1 | $1.38M | Hold |
7,600
| – | – | 0.51% | 41 |
|
|
2023
Q4 | $1.18M | Hold |
7,600
| – | – | 0.47% | 44 |
|
|
2023
Q3 | $1.13M | Hold |
7,600
| – | – | 0.52% | 44 |
|
|
2023
Q2 | $1.02M | Hold |
7,600
| – | – | 0.46% | 46 |
|
|
2023
Q1 | $1.21M | Sell |
7,600
-300
| -4% | -$45.9K | 0.59% | 42 |
|
|
2022
Q4 | $1.28M | Sell |
7,900
-935
| -11% | -$143K | 0.65% | 42 |
|
|
2022
Q3 | $1.19M | Sell |
8,835
-100
| -1% | -$14.3K | 0.63% | 43 |
|
|
2022
Q2 | $1.37M | Sell |
8,935
-30
| -0.3% | -$4.58K | 0.85% | 37 |
|
|
2022
Q1 | $1.45M | Sell |
8,965
-525
| -6% | -$76.3K | 0.6% | 43 |
|
|
2021
Q4 | $1.28M | Sell |
9,490
-100
| -1% | -$11.8K | 0.5% | 44 |
|
|
2021
Q3 | $1.03M | Sell |
9,590
-35
| -0.4% | -$4K | 0.47% | 45 |
|
|
2021
Q2 | $1.08M | Hold |
9,625
| – | – | 0.49% | 44 |
|
|
2021
Q1 | $1.04M | Sell |
9,625
-21
| -0.2% | -$2.25K | 0.52% | 45 |
|
|
2020
Q4 | $1.03M | Buy |
+9,646
| New | +$927K | 0.6% | 38 |
|
|
2020
Q2 | – | Sell |
-12,935
| Closed | -$986K | – | 50 |
|
|
2020
Q1 | $986K | Hold |
12,935
| – | – | 0.91% | 31 |
|
|
2019
Q4 | $1.15M | Sell |
12,935
-805
| -6% | -$66.8K | 0.78% | 39 |
|
|
2019
Q3 | $1.04M | Sell |
13,740
-385
| -3% | -$26.4K | 0.78% | 41 |
|
|
2019
Q2 | $1.03M | Sell |
14,125
-790
| -5% | -$62.1K | 0.83% | 36 |
|
|
2019
Q1 | $1.2M | Sell |
14,915
-85
| -0.6% | -$6.95K | 0.92% | 32 |
|
|
2018
Q4 | $1.38M | Sell |
15,000
-200
| -1% | -$17.6K | 1.19% | 25 |
|
|
2018
Q3 | $1.44M | Buy |
15,200
+2,885
| +23% | +$274K | 1.04% | 27 |
|
|
2018
Q2 | $1.14M | Sell |
12,315
-550
| -4% | -$53.7K | 0.98% | 34 |
|
|
2018
Q1 | $1.22M | Sell |
12,865
-1,130
| -8% | -$124K | 0.97% | 31 |
|
|
2017
Q4 | $1.35M | Sell |
13,995
-750
| -5% | -$70.7K | 1.03% | 31 |
|
|
2017
Q3 | $1.31M | Sell |
14,745
-1,330
| -8% | -$101K | 1.02% | 32 |
|
|
2017
Q2 | $1.17M | Sell |
16,075
-1,833
| -10% | -$123K | 0.95% | 35 |
|
|
2017
Q1 | $1.17M | Sell |
17,908
-500
| -3% | -$31.4K | 0.96% | 35 |
|
|
2016
Q4 | $1.15M | Sell |
18,408
-477
| -3% | -$29.1K | 1.01% | 35 |
|
|
2016
Q3 | $1.19M | Buy |
18,885
+200
| +1% | +$12.9K | 1.06% | 33 |
|
|
2016
Q2 | $1.16M | Buy |
18,685
+100
| +0.5% | +$6.09K | 1.05% | 31 |
|
|
2016
Q1 | $1.06M | Sell |
18,585
-315
| -2% | -$17.6K | 1.02% | 35 |
|
|
2015
Q4 | $1.12M | Sell |
18,900
-4,205
| -18% | -$242K | 1.08% | 31 |
|
|
2015
Q3 | $1.26M | Sell |
23,105
-2,850
| -11% | -$186K | 1.26% | 25 |
|
|
2015
Q2 | $1.74M | Buy |
+25,955
| New | +$1.69M | 1.59% | 22 |
|
Other funds holding ABBV
Westbourne Investment Advisors's ABBV Position: Q2 2026 in Review
Westbourne Investment Advisors reduced its AbbVie (ABBV) stake by 4.3% in Q2 2026, selling an estimated $64.5K and leaving 6,625 shares worth $1.67M. The position accounts for 0.46% of the portfolio, ranked #39.
Westbourne Investment Advisors first reported a position in ABBV in Q2 2015 and has held it in 43 quarters since. The position peaked at $1.74M in Q2 2015. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Westbourne Investment Advisors held 6,625 shares of AbbVie worth $1.67M as of Q2 2026.
- Westbourne Investment Advisors sold 300 AbbVie shares in Q2 2026, an estimated $64.5K.
- AbbVie made up 0.46% of Westbourne Investment Advisors's portfolio in Q2 2026, its #39 holding.
- Westbourne Investment Advisors first reported a position in AbbVie in Q2 2015 and has held it in 43 quarters since.
- Westbourne Investment Advisors's AbbVie position peaked at $1.74M in Q2 2015.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Westbourne Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.